GILD Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Gilead Sciences Inc - Alpha Spread

Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 85.21 USD 0.92% Market Closed
Market Cap: 106.2B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Wall Street
Price Targets

GILD Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GILD stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GILD is 83.98 USD with a low forecast of 69.19 USD and a high forecast of 124.95 USD.

Lowest
Price Target
69.19 USD
19% Downside
Average
Price Target
83.98 USD
1% Downside
Highest
Price Target
124.95 USD
47% Upside

GILD Last Price Targets
Gilead Sciences Inc

The latest public price target was made on Sep 23, 2024 by Michael Yee from Jefferies , who expects GILD stock to rise by 11% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Michael Yee
Jefferies
95 USD
Upside 11%
2 weeks ago
Sep 23, 2024
Jefferies on Gilead Sciences (GILD): 'Competitor Dato surprise setback in breast cancer, new incremental (+) for GILD'
StreetInsider
Salveen Richter
Goldman Sachs
71 USD
Downside 17%
3 weeks ago
Sep 12, 2024
Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)
StreetInsider
Terence Flynn
Morgan Stanley
79 USD
Downside 7%
3 weeks ago
Sep 12, 2024
Gilead lenacapavir data 'an expected positive,' says Morgan Stanley
TheFly
Joseph Catanzaro
Piper Sandler
95 USD
Upside 11%
4 weeks ago
Sep 11, 2024
Piper Sandler Reiterates Overweight Rating on Gilead Sciences (GILD)
StreetInsider
Asthika Goonewardene
Truist Financial
83 USD
Downside 3%
1 month ago
Aug 14, 2024
Gilead Sciences (GILD) PT Raised to $83 at Truist Securities
StreetInsider
Evan David Seigerman
BMO Capital
85 USD
Downside 0%
2 months ago
Aug 9, 2024
Gilead Sciences (GILD) PT Raised to $85 at BMO Capital
StreetInsider
Brian Abrahams
RBC Capital
72 USD
Downside 16%
2 months ago
Aug 9, 2024
Gilead Sciences (GILD) PT Raised to $72 at RBC Capital
StreetInsider
Steven Seedhouse
Raymond James
93 USD
Upside 9%
3 months ago
Jul 8, 2024
Raymond James Upgrades Gilead Sciences (GILD) to Outperform
StreetInsider
Michael Yee
Jefferies
85 USD
Downside 0%
3 months ago
Jun 24, 2024
Gilead price target raised to $85 from $80 at Jefferies
TheFly
Brian Skorney
Robert W. Baird
80 USD
Downside 6%
3 months ago
Jun 20, 2024
Baird on Gilead Sciences (GILD): 'Incrementally positive on clinical data'
StreetInsider
Salim Syed
Mizuho Securities
90 USD
Upside 6%
3 months ago
Jun 17, 2024
Gilead Sciences (GILD) GS-4571 Intended for NASH Not Obesity - Mizuho
StreetInsider
Brian Abrahams
RBC Capital
74 USD
Downside 13%
3 months ago
Jun 14, 2024
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
StreetInsider
Evan David Seigerman
BMO Capital
80 USD
Downside 6%
4 months ago
May 20, 2024
BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
StreetInsider
Morten Herholdt
HSBC
69 USD
Downside 19%
5 months ago
Apr 24, 2024
HSBC Upgrades Gilead Sciences (GILD) to Hold
StreetInsider
Brian Abrahams
RBC Capital
76 USD
Downside 11%
7 months ago
Feb 14, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Brian Abrahams
RBC Capital
84 USD
Downside 1%
1 year ago
Sep 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Geoff Meacham
Bank of America Securities
95 USD
Upside 11%
1 year ago
Sep 8, 2023
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Benzinga
Unknown Analyst
Leerink Partners
91 USD
Upside 7%
1 year ago
Feb 3, 2023
SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to $91
Benzinga
Unknown Analyst
Piper Sandler
112 USD
Upside 31%
1 year ago
Feb 3, 2023
Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $112
Benzinga
Show More Price Targets
Show Less Price Targets
Michael Yee
Jefferies
Price Target 95 USD
Upside/Downside 11%
View Source
Salveen Richter
Goldman Sachs
Price Target 71 USD
Upside/Downside 17%
View Source
Terence Flynn
Morgan Stanley
Price Target 79 USD
Upside/Downside 7%
View Source
Joseph Catanzaro
Piper Sandler
Price Target 95 USD
Upside/Downside 11%
View Source
Asthika Goonewardene
Truist Financial
Price Target 83 USD
Upside/Downside 3%
View Source
Evan David Seigerman
BMO Capital
Price Target 85 USD
Upside/Downside 0%
View Source
Brian Abrahams
RBC Capital
Price Target 72 USD
Upside/Downside 16%
View Source
Steven Seedhouse
Raymond James
Price Target 93 USD
Upside/Downside 9%
View Source
Michael Yee
Jefferies
Price Target 85 USD
Upside/Downside 0%
View Source
Brian Skorney
Robert W. Baird
Price Target 80 USD
Upside/Downside 6%
View Source
Salim Syed
Mizuho Securities
Price Target 90 USD
Upside/Downside 6%
View Source
Brian Abrahams
RBC Capital
Price Target 74 USD
Upside/Downside 13%
View Source
Evan David Seigerman
BMO Capital
Price Target 80 USD
Upside/Downside 6%
View Source
Morten Herholdt
HSBC
Price Target 69 USD
Upside/Downside 19%
View Source
Brian Abrahams
RBC Capital
Price Target 76 USD
Upside/Downside 11%
View Source
Brian Abrahams
RBC Capital
Price Target 84 USD
Upside/Downside 1%
View Source
Geoff Meacham
Bank of America Securities
Price Target 95 USD
Upside/Downside 11%
View Source
Unknown Analyst
Leerink Partners
Price Target 91 USD
Upside/Downside 7%
View Source
Unknown Analyst
Piper Sandler
Price Target 112 USD
Upside/Downside 31%
View Source
Show More Price Targets
Show Less Price Targets
Gilead Sciences Inc Competitors:
Price Targets
OCX
OncoCyte Corp
26% Upside
4891
TMS Co Ltd
319% Upside
XNCR
Xencor Inc
78% Upside
2160
GNI Group Ltd
35% Upside
TNG
Transgene SA
165% Upside
COYA
Coya Therapeutics Inc
128% Upside
ARWR
Arrowhead Pharmaceuticals Inc
168% Upside
NIOX
Niox Group PLC
20% Upside

Revenue
Forecast

Revenue Estimate
Gilead Sciences Inc

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's revenue is -2%. The projected CAGR for the next 3 years is 3%.

-2%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gilead Sciences Inc

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's operating income is -10%. The projected CAGR for the next 3 years is 8%.

-10%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-18%
Average Miss

Net Income
Forecast

Net Income Estimate
Gilead Sciences Inc

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's net income is -14%. The projected CAGR for the next 3 years is 20%.

-14%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-40%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GILD's stock price target?
Price Target
83.98 USD

According to Wall Street analysts, the average 1-year price target for GILD is 83.98 USD with a low forecast of 69.19 USD and a high forecast of 124.95 USD.

What is Gilead Sciences Inc's Revenue forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's revenue is -2%. The projected CAGR for the next 3 years is 3%.

What is Gilead Sciences Inc's Operating Income forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's operating income is -10%. The projected CAGR for the next 3 years is 8%.

What is Gilead Sciences Inc's Net Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's net income is -14%. The projected CAGR for the next 3 years is 20%.

Back to Top